FDA approves Lilly breast cancer med for expanded use

Feb 27, 2018

The U.S. Food and Drug Administration have approved expanded use of Eli Lilly’s Verzenio (abemaciclib) breast cancer drug when used as an initial treatment for certain women with advanced or metastatic disease.

The oral drug, which competes with Pfizer’s Ibrance and Novartis's Kisqali, was originally approved last September in combination with AstraZeneca’s Faslodex (fulvestrant).

The latest approval comes after a late-stage study that found the Lilly drug, when taken twice daily with anastrozole or letrozole significantly delayed disease progression.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments